Abstract
Objective: The aim of this study was to assess the security, value, and efficacy of the second-generation AdVance male sling XP (Boston Scientific®), after implementation in 2010 with advantageous modifications in the sling structure and needle shape, in a prospective multicenter long-term follow-up study. Methods: In total, 115 patients were included. Exclusion criteria were earlier incontinence (UI) surgery, nocturnal UI, former radiotherapy, or night-time incontinence. We also excluded patients with a functional urethra <1 cm in a preoperatively performed repositioning test. A consistent 24-h pad test, International Quality of Life (IQOL) score, visual analog pain scale (VAS), International Consultation-Incontinence Questionnaire (ICIQ-UI SF), International Index of Erectile Function (IIEF-5), International Prostate Symptom Score (IPSS), and Patient Global Impression of Improvement (PGI-I) scores were requested postoperatively. Results: The 24-month follow-up (114 patients) revealed 64.0% cured and 28.8% improved patients. Mean urine loss was reduced significantly to 19.0 g (p < 0.001). A mean PGI score of 1.5 and a mean VAS score of 0.2 were obtained. The 60-month follow-up (59 patients) revealed 57.6% cured and 25.4% improved patients. Mean urine loss was reduced significantly to 18.3 g (p < 0.001). A mean PGI score of 1.6 and a mean VAS score of 0.2 were obtained. Conclusions: The AdVance XP displays excellent continence results and secure effectiveness over a 5-year period. Moreover, these data are demonstrating low complication rates and improved quality of life in the long-term use of AdVance XP.
Journal Section:
Editor's choice
References
1.
Lucas
MG
, Bosch
RJ
, Burkhard
FC
, Cruz
F
, Madden
TB
, Nambiar
AK
, . EAU guidelines on surgical treatment of urinary incontinence
. Actas Urol Esp
. 2013
;37
(8
):459
–72
.2.
Stanford
JL
, Feng
Z
, Hamilton
AS
, Gilliland
FD
, Stephenson
RA
, Eley
JW
, . Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study
. JAMA
. 2000
;283
(3
):354
–60
.3.
Nam
RK
, Herschorn
S
, Loblaw
DA
, Liu
Y
, Klotz
LH
, Carr
LK
, . Population based study of long-term rates of surgery for urinary incontinence after radical prostatectomy for prostate cancer
. J Urol
. 2012
;188
(2
):502
–6
.4.
Kumar
A
, Litt
ER
, Ballert
KN
, Nitti
VW
. Artificial urinary sphincter versus male sling for post-prostatectomy incontinence: What do patients choose
. J Urol
. 2009
;181
(3
):1231
–5
.5.
Hoy
NY
, Rourke
KF
. Stemming the tide of mild to moderate post-prostatectomy incontinence: a retrospective comparison of transobturator male slings and the artificial urinary sphincter
. Can Urol Assoc J
. 2014
;8
(7–8
):273
–7
.6.
Rehder
P
, Gozzi
C
. Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy
. Eur Urol
. 2007
;52
(3
):860
–6
.7.
Rehder
P
, Staudacher
NM
, Schachtner
J
, Berger
ME
, Schillfahrt
F
, Hauser
V
, . Hypothesis that urethral bulb (corpus spongiosum) plays an active role in male urinary continence
. Adv Urol
. 2016
;2016
:6054730
.8.
Kretschmer
A
, Hübner
W
, Sandhu
JS
, Bauer
RM
. Evaluation and management of postprostatectomy incontinence: a systematic review of current literature
. Eur Urol Focus
. 2016
;2
(3
):245
–59
.9.
Bauer
RM
, Mayer
ME
, May
F
, Gratzke
C
, Buchner
A
, Soljanik
I
, . Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence
. Urology
. 2010
;75
(6
):1494
–8
.10.
Bauer
RM
, Mayer
ME
, Gratzke
C
, Soljanik
I
, Buchner
A
, Bastian
PJ
, . Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: results after 1 year
. Eur Urol
. 2009
;56
(6
):928
–33
.11.
Papachristos
A
, Mann
S
, Talbot
K
, Moon
D
. AdVance male urethral sling: medium-term results in an Australian cohort
. ANZ J Surg
. 2018
;88
(3
):E178
–82
.12.
Bauer
RM
, Grabbert
MT
, Klehr
B
, Gebhartl
B
, Gozzi
C
, Homberg
R
, . 36-month data for the AdVance XP® male sling: results of a prospective multicentre study
. BJU Int
. 2017
;119
(4
):626
–30
.13.
Cornu
JN
, Sèbe
P
, Ciofu
C
, Peyrat
L
, Cussenot
O
, Haab
F
. Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors
. BJU Int
. 2011
;108
(2
):236
–40
.14.
Zemp
L
, Tong
S
, Hoy
N
, Rourke
KF
. Preoperative pad usage is independently associated with failure of non-adjustable male trans-obturator slings in otherwise well-selected patients
. Can Urol Assoc J
. 2019
;13
(4
):120
–4
.15.
Ye
H
, Haab
F
, de Ridder
D
, Chauveau
P
, Becker
A
, Arano
P
, . Effectiveness and complications of the AMS AdVance male sling system for the treatment of stress urinary incontinence: a prospective multicenter study
. Urology
. 2018
;120
:197
–204
.16.
Kretschmer
A
, Grabbert
M
, Sommer
A
, Stief
CG
, Bauer
RM
. Mid-term outcomes after AdVanceXP male sling implantation
. BJU Int
. 2016
;118
(3
):458
.17.
Bauer
RM
, Rutkowski
M
, Kretschmer
A
, Casuscelli
J
, Stief
CG
, Huebner
W
. Efficacy and complications of the adjustable sling system ArgusT for male incontinence: results of a prospective 2-center study
. Urology
. 2015
;85
(2
):316
–20
.18.
Bauer
RM
, Gozzi
C
, Klehr
B
, Kretschmer
A
, Grabbert
M
, Rehder
P
, . AdVanceXP male sling: 2-year results of a multicentre study
. World J Urol
. 2016
;34
(7
):1025
–30
.19.
Grabbert
M
, Mumm
JN
, Klehr
B
, Kretschmer
A
, Gebhartl
P
, Gozzi
C
, . Extended follow-up of the AdVance XP male sling in the treatment of male urinary stress incontinence after 48 months: results of a prospective and multicenter study
. Neurourol Urodyn
. 2019 Sep
;38
(7
):1973
–8
.20.
Bauer
RM
, Kretschmer
A
, Stief
CG
, Füllhase
C
. AdVance and AdVance XP slings for the treatment of post-prostatectomy incontinence
. World J Urol
. 2015
;33
(1
):145
–50
.21.
Bushnell
DM
, Martin
ML
, Summers
KH
, Svihra
J
, Lionis
C
, Patrick
DL
. Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL
. Qual Life Res
. 2005
;14
(8
):1901
–13
.22.
Avery
K
, Donovan
J
, Peters
TJ
, Shaw
C
, Gotoh
M
, Abrams
P
. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence
. Neurourol Urodyn
. 2004
;23
(4
):322
–30
.23.
Twiss
CO
, Fischer
MC
, Nitti
VW
. Comparison between reduction in 24-hour pad weight, International Consultation on Incontinence-Short Form (ICIQ-SF) score, International Prostate Symptom Score (IPSS), and Post-Operative Patient Global Impression of Improvement (PGI-I) score in patient evaluation after male perineal sling
. Neurourol Urodyn
. 2007
;26
(1
):8
–13
.24.
Clavien
PA
, Barkun
J
, de Oliveira
ML
, Vauthey
JN
, Dindo
D
, Schulick
RD
, . The Clavien-Dindo classification of surgical complications: five-year experience
. Ann Surg
. 2009
;250
(2
):187
–96
.25.
Bauer
RM
, Gozzi
C
, Roosen
A
, Khoder
W
, Trottmann
M
, Waidelich
R
, . Impact of the ‘repositioning test’ on postoperative outcome of retroluminar transobturator male sling implantation
. Urol Int
. 2013
;90
(3
):334
–8
.26.
Dindo
D
, Demartines
N
, Clavien
PA
. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey
. Ann Surg
. 2004
;240
(2
):205
–13
.27.
Cornu
JN
, Batista Da Costa
J
, Henry
N
, Peyrat
L
, Beley
S
, Haab
F
. Comparative study of AdVance and AdVanceXP male slings in a tertiary reference center
. Eur Urol
. 2014
;65
(2
):502
–4
.28.
Soljanik
I
, Bauer
RM
, Stief
CG
, Gozzi
C
, Becker
AJ
. Pelvic floor muscle function is an independent predictor of outcome after retrourethral transobturator male sling procedure
. World J Urol
. 2015
;33
(8
):1143
–9
.29.
Husch
T
, Kretschmer
A
, Thomsen
F
, Kronlachner
D
, Kurosch
M
, Obaje
A
, . The AdVance and AdVanceXP male sling in urinary incontinence: Is there a difference
. World J Urol
. 2018
;36
(10
):1657
–62
.30.
Lai
HH
, Hsu
EI
, Teh
BS
, Butler
EB
, Boone
TB
. 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine
. J Urol
. 2007
;177
(3
):1021
–5
.31.
Zuckerman
JM
, Edwards
B
, Henderson
K
, Beydoun
HA
, McCammon
KA
. Extended outcomes in the treatment of male stress urinary incontinence with a transobturator sling
. Urology
. 2014
;83
(4
):939
–45
.32.
Bauer
RM
, Gozzi
C
, Klehr
B
, Kretschmer
A
, Grabbert
M
, Rehder
P
, . AdVance XP male sling: 2-year results of a multicentre study
. World J Urol
. 2016 Jul
;34
(7
):1025
–30
.33.
Rehder
P
, Haab
F
, Cornu
JN
, Gozzi
C
, Bauer
RM
. Treatment of postprostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3-year follow-up
. Eur Urol
. 2012
;62
(1
):140
–5
.34.
Sturm
RM
, Guralnick
ML
, Stone
AR
, Bales
GT
, Dangle
PP
, O’Connor
RC
. Comparison of clinical outcomes between “ideal” and “nonideal” transobturator male sling patients for treatment of postprostatectomy incontinence
. Urology
. 2014
;83
(5
):1186
–8
.35.
Kowalik
CG
, DeLong
JM
, Mourtzinos
AP
. The advance transobturator male sling for post-prostatectomy incontinence: subjective and objective outcomes with 3 years follow up
. Neurourol Urodyn
. 2015
;34
(3
):251
–4
.36.
Collado
A
, Domínguez-Escrig
J
, Ortiz Rodríguez
IM
, Ramirez-Backhaus
M
, Rodríguez Torreblanca
C
, Rubio-Briones
J
, . Functional follow-up after Advance® and Advance XP® male sling surgery: assessment of predictive factors
. World J Urol
. 2019
;37
(1
):195
–200
.© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
